What is the current Price Target for the Galera Therapeutics Inc stock?

The average Galera Therapeutics Inc target price is $0.38. This is 1,316.67% higher than the current stock price. The highest price target is 1,844.44%, the lowest is 835.19%. 4 Analysts have issued a price target Galera Therapeutics Inc 2026 .

How high will the Galera Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Galera Therapeutics Inc stock will rise. The performance of stocks, including the Galera Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Galera Therapeutics Inc stock today?

The performance of Galera Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Galera Therapeutics Inc stock fall?

The decline in Galera Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Galera Therapeutics Inc Forecast, price target & analysts

$0.03

3.70% today

Nasdaq, Jul 14, 07:09 pm CET

ISIN

US36338D1081

Symbol

GRTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts Strategies

Galera Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Galera Therapeutics Inc Classifications & Recommendation:

Hold

57%

Sell

43%

Galera Therapeutics Inc Price Target

Target Price	$0.38
Price	$0.03
Potential	1,316.67% register free of charge
Number of Estimates	4

	4 Analysts have issued a price target Galera Therapeutics Inc 2026 . The average Galera Therapeutics Inc target price is $0.38. This is 1,316.67% register free of charge higher than the current stock price. The highest price target is $0.53 1,844.44% register free of charge , the lowest is $0.25 835.19% register free of charge .
	A rating was issued by 7 analysts: 0 Analysts recommend Galera Therapeutics Inc to buy, 4 to hold and 3 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Galera Therapeutics Inc stock has an average upside potential 2026 of 1,316.67% register free of charge . Most analysts recommend the Galera Therapeutics Inc stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.35	-0.80
	73.68%	128.57%
P/E		negative
EV/Sales		1.15

3 Analysts have issued a Galera Therapeutics Inc forecast for earnings per share. The average Galera Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.35	73.68%
2025	$-0.80 128.57% Unlock

Current	-0.17	32.70%
2025	-0.03 82.23% Unlock

Galera Therapeutics Inc...

Discover more stocks with a high price target

Alibaba Group Holding Ltd 53.61%

Tencent Holdings Ltd. 30.43%

Adyen 30.39%

Adidas 28.61%

Deutsche Telekom 26.75%

BioNTech SE - ADR 24.24%

NIO ADR 21.62%

PayPal 14.35%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now